Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | Zendy

José Baselga | Zendy; Mario Campone | Zendy; Martine Piccart | Zendy; Howard A. Burris | Zendy; Hope S. Rugo | Zendy; Tarek Sahmoud | Zendy; Shinzaburo Noguchi | Zendy; Michael Gnant | Zendy; Kathleen I. Pritchard | Zendy; Fabienne Lebrun | Zendy; J. Thaddeus Beck | Zendy; Yoshinori Ito | Zendy; Denise A. Yardley | Zendy; Ines Deleu | Zendy; Alejandra Perez | Zendy; Thomas Bachelot | Zendy; Luc Vittori | Zendy; Zhiying Xu | Zendy; Pabak Mukhopadhyay | Zendy; David Lebwohl | Zendy; Gabriel N. Hortobágyi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Author(s) -

José Baselga,

Mario Campone,

Martine Piccart,

Howard A. Burris,

Hope S. Rugo,

Tarek Sahmoud,

Shinzaburo Noguchi,

Michael Gnant,

Kathleen I. Pritchard,

Fabienne Lebrun,

J. Thaddeus Beck,

Yoshinori Ito,

Denise A. Yardley,

Ines Deleu,

Alejandra Perez,

Thomas Bachelot,

Luc Vittori,

Zhiying Xu,

Pabak Mukhopadhyay,

David Lebwohl,

Gabriel N. Hortobágyi

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1109653

Subject(s) - everolimus , medicine , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , endocrine system , breast cancer , hormone receptor , sirolimus , hormone , cancer research , cancer , oncology , endocrinology , signal transduction , biology , microbiology and biotechnology

Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research